Novel Technologies: A Weapon Against Tuberculosis

Overview

Journal Indian J Pharmacol

Specialty Pharmacology

Date 2010 Dec 31

PMID 21189901

Citations 2

Authors

B N Vedha Hari

Karuna Priya Chitra

Ramadevi Bhimavarapu

Prabhu Karunakaran

N Muthukrishnan

B Samyuktha Rani

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) is a leading chronic bacterial infection. Despite potentially curative pharmacotherapies being available for over 50 years, the length of the treatment and the pill burden can hamper patient lifestyle. Low compliance and adherence to administration schedules remain the main reasons for therapeutic failure and contribute to the development of multidrug-resistant strains. The design of novel antibiotics attempts to overcome drug resistance, to shorten the treatment course, and to reduce drug interactions. In this framework, nanotechnology appears as one of the promising approaches for the development of more effective medicines. The present review thoroughly overviews the development of novel microparticulate, encapsulation, and various other carrier-based drug delivery systems for incorporating the principal anti-TB agents. Drug delivery systems have been designed that either target the site of TB or reduce the dosing frequency with the aim of improving patient healthcare.

Citing Articles

Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy.

Hlaka L, Rosslee M, Ozturk M, Kumar S, Parihar S, Brombacher F J Antimicrob Chemother. 2017; 72(12):3334-3341.

PMID: 28961913 PMC: 5890746. DOI: 10.1093/jac/dkx326.

Nanotechnology-Based Approach in Tuberculosis Treatment.

Nasiruddin M, Neyaz M, Das S Tuberc Res Treat. 2017; 2017:4920209.

PMID: 28210505 PMC: 5292193. DOI: 10.1155/2017/4920209.

References

Gregoriadis G, Wills E, Swain C, TAVILL A . Drug-carrier potential of liposomes in cancer chemotherapy. Lancet. 1974; 1(7870):1313-6. DOI: 10.1016/s0140-6736(74)90682-5. View

Seki J, Sonoke S, Saheki A, Fukui H, Sasaki H, Mayumi T . A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting. Int J Pharm. 2004; 273(1-2):75-83. DOI: 10.1016/j.ijpharm.2003.12.022. View

Sham J, Zhang Y, Finlay W, Roa W, Lobenberg R . Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm. 2004; 269(2):457-67. DOI: 10.1016/j.ijpharm.2003.09.041. View

Loftsson T, Duchene D . Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2006; 329(1-2):1-11. DOI: 10.1016/j.ijpharm.2006.10.044. View

Azarmi S, Roa W, Lobenberg R . Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008; 60(8):863-75. DOI: 10.1016/j.addr.2007.11.006. View

Owens 3rd D, Peppas N . Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2005; 307(1):93-102. DOI: 10.1016/j.ijpharm.2005.10.010. View

Constantinides P, Chaubal M, Shorr R . Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv Drug Deliv Rev. 2007; 60(6):757-67. DOI: 10.1016/j.addr.2007.10.013. View

du Toit L, Pillay V, Danckwerts M . Tuberculosis chemotherapy: current drug delivery approaches. Respir Res. 2006; 7:118. PMC: 1592088. DOI: 10.1186/1465-9921-7-118. View

Soppimath K, Aminabhavi T, Kulkarni A, Rudzinski W . Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001; 70(1-2):1-20. DOI: 10.1016/s0168-3659(00)00339-4. View

10.

Muttil P, Wang C, Hickey A . Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2010; 26(11):2401-16. DOI: 10.1007/s11095-009-9957-4. View

11.

Junyaprasert V, Teeranachaideekul V, Supaperm T . Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS PharmSciTech. 2008; 9(3):851-9. PMC: 2977041. DOI: 10.1208/s12249-008-9121-1. View

12.

Visscher G, Robison R, Maulding H, Fong J, Pearson J, Argentieri G . Biodegradation of and tissue reaction to poly(DL-lactide) microcapsules. J Biomed Mater Res. 1986; 20(5):667-76. DOI: 10.1002/jbm.820200510. View

13.

DEmanuele A, Attwood D . Dendrimer-drug interactions. Adv Drug Deliv Rev. 2005; 57(15):2147-62. DOI: 10.1016/j.addr.2005.09.012. View

14.

Kataoka K, Harada A, Nagasaki Y . Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2001; 47(1):113-31. DOI: 10.1016/s0169-409x(00)00124-1. View

15.

Onyebujoh P, Zumla A, Ribeiro I, Rustomjee R, Mwaba P, Gomes M . Treatment of tuberculosis: present status and future prospects. Bull World Health Organ. 2005; 83(11):857-65. PMC: 2626471. DOI: /S0042-96862005001100016. View

16.

Croy S, Kwon G . Polymeric micelles for drug delivery. Curr Pharm Des. 2006; 12(36):4669-84. DOI: 10.2174/138161206779026245. View

17.

Delie F, Blanco-Prieto M . Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules. 2007; 10(1):65-80. PMC: 6147556. DOI: 10.3390/10010065. View

18.

Brewster M, Loftsson T . Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 2007; 59(7):645-66. DOI: 10.1016/j.addr.2007.05.012. View

19.

Iseman M . Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993; 329(11):784-91. DOI: 10.1056/NEJM199309093291108. View

20.

Dye C . Global epidemiology of tuberculosis. Lancet. 2006; 367(9514):938-40. DOI: 10.1016/S0140-6736(06)68384-0. View